Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

With the current biotherapeutic market dominated by antibody molecules, bispecific
antibodies represent a key component of the next-generation of antibody therapy. Bispecific …

Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …

The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

The therapeutic use of bispecific T‐cell engaging (BiTE) antibodies has shown great
potential for treating malignancies. BiTE can simultaneously engage CD3ε on T cells and …

Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …

Bispecific antibodies have moved from being an academic curiosity with therapeutic promise
to reality, with two molecules being currently commercialized (Hemlibra® and Blincyto®) …

Immunotherapy of cancer with CD3-targeting bispecific antibodies (CD3 bsAb) is a fast
developing field, and multiple tumor-associated antigens (TAA) are evaluated for …